Roche cracks China's ADC market open as Kadcyla scores its first breast cancer OK in the country

Roche’s Kadcyla has become the first antibody-drug conjugate to enter the Chinese market, marking a dramatic advance for both the Swiss pharma giant and the therapeutic class.